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Motivation of the paper
 To explore how scientists’ brokerage positions facilitates their participation in
different forms of medical innovation?
 To analyze whether all types of brokerage are equally effective in facilitating the
scientists’ engagement in various innovation-related activities.
 To explore whether brokerage operates differently under different institutional
contexts
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Background: medical innovation and network brokerage
Knowledge brokerage: definition
In network research, a brokerage position is characterized by the absence of ties
between the contacts of a focal actor.
Formally, a knowledge broker (A) is a focal actor who mediates the flow of knowledge
between two other unconnected actors (Burt, 1992, Wasserman & Faust, 1994)
A
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Background: medical innovation and network brokerage
What is behind the network advantage
Network theory predicts that knowledge brokers’ advantage come in two forms:
 An information advantage. Being a broker provides more opportunities to:
- …tap into diverse knowledge
- …spot similarities between seemingly unrelated knowledge
- …synthesize apparently contradictory points of view
- …come up with novel ideas
 A timing advantage. Brokers have a faster access to new knowledge (Burt, 1997, 2007).
Therefore, in a competitive process in which timing is rewarded, a brokerage position
may provide a crucial advantage.
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Network brokerage and medical innovation
 Brokerage positions also entails coordination and cognitive costs for the focal actor:
The dark side of brokerage positions
Coordination costs Cognitive costs
Coordination costs accrue from the structure
of the network (keeping and maintaining a
large set of unconnected contacts)
Cognitive costs accrue from the content of
the network (dealing with an overload of
disparate knowledge and interests)
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Maintaining a too large set of brokerage positions
may distract the focal actor to engage on
innovation-related activities (Perry-Smith & Shalley,
2003).
A large set of unconnected contacts undermines
the creation of trust between the network
members and thus, hinders the transfer of tacit
knowledge (Coleman, 1998, Hansen, 1999)
When the number of ties is too large, individuals
are likely to experience information overload: They
may be unable to cope with voluminous and
discordant information (Zhou et al. 2009)
Dispersed people found around structural holes are
inherently more difficult to mobilize or coordinate,
due to disparate interests, perspectives and
languages.
Brokerage roles and medical innovation 
 To disentangle the benefits and costs of brokerage positions on innovation, we propose
to analytically decompose brokerage positions into distinct types.
 Different brokerage roles can be recognized based on the type of actors each node is
connected to (Gould & Fernandez, 1989).
Ego
BA
Ego
BA
Ego
BA
Ego
BA
Liaison Gatekeeper Consultant Coordinator
*Colours represent different institutional affiliations or professional groups
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brokerage roles
Knowledge diversity Cognitive costs Coordination  costs
Liaison ++++ ++++ constant
Gatekeeper ++ ++ constant
Consultant ++ +++ constant
Coordinator + + constant
 The potential benefits and costs of brokerage partly depend on the diversity of actors
involved in the triadic relationship.
 Liaison positions means the greater access to heterogeneous actors and thus, a greatest potential to access to new
knowledge.
 Coodinator positions provides the lowest access to diverse knowledge.
 But: dealing with more diverse actors in the network also demands higher cognitive efforts for the focal actor to
understand an manage a diversity of knowledge and interests.
 Therefore, cognitive costs depend on the type brokerage role played by the focal actor. Conversely, coordination
costs increase irrespective of the brokerage role because they arise from keeping and maintaining a large set of
unconnected contacts.
Distinctive effects of brokerage roles on medical innovation
Higher knowledge
diversity
Lower knowledge
diversity
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 Gatekeeper positions will provide the greater balance between benefits and costs of
brokerage. Thus, gatekeeper positions will be more strongly associated to the scientists’
participation in a range of medical innovation activities, compared to other positions.
Hypothesis 1: There is a positive association between holding gatekeeper positions and 
participating in medical innovation activities.
 Coordinator positions involve brokering two contacts pertaining to the same group as the
focal scientist. Thus, for coordinator positions, the potential costs of being a broker will
surpass its potential benefits.
Hypothesis 2: There is a negative association between holding coordinator positions and 
participating in medical innovation activities.
Distinctive effects of brokerage roles: hypoteses
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The influence of the institutional context
 Growing empirical evidence on network effects, but scarce attention to the institutional
and organizational context where social interactions take place (Pachucki & Brieger 2010).
 We know that the institutional settings where scientists work present distinctive goals,
values, incentive structuresand cultural norms (Dasgupta & David 1994, Whitley 2000)
 In hospital settings the participation in medical innovation activities is partly embedded
in the values and institutional norms. Moreover, access to critical contacts and resources
to do so might be more easily found inside the institution.
Hypothesis 3: Working in hospital settings weakens the positive connection between
gatekeeper positions and participation in medical innovation activities.
9
Spanish Biomedical Research Networking Centers (CIBERs) are formal networks structures
created by the Spanish Ministry of Health in 2007.
Aims of the CIBER networks:
 Bring together scientists from universities, hospitals and research centers working on similar
fields.
 Organize biomedical research around nine pathologies of critical interest for the Spanish’
National Health System:
 Neurodegenerative diseases
 Rare diseases
 Hepatic diseases
 Bioengineering, Biomaterials and Nanomedicine
 Epidemiology and Public Health
 Obesity and Nutrition
 Respiratory Diseases
 Mental Health
 Diabetes and Metabolic Associated Diseases
Research context and methods
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Research context and methods (ii)
Sample frame for the study:
All biomedical scientists and technicians belonging to each of the nine CIBER networks (4,758
individuals).
Implementation of a survey
We designed a questionnaire to identify each scientist’ collaborative network (external to
his/her research team), their individual attributes and their degree of engagement in multiple
activities related to medical innovation.
Overall response rate = 28 % (1,309 valid responses)
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Items
Patent applications for new drugs
Granted licenses from patents
Participation in spin-off
Clinical trials phases I, II or III for new drugs development
Clinical trials phase IV for new drugs development
Clinical trials phase IV for new diagnostic techniques
Clinical guidelines for healthcare professionals
Clinical guidelines for patients
Patent applications for new diagnostic techniques
Clinical trials phases I, II or III for new diagnostic techniques
Clinical guidelines for the general population (prevention)
Dependent variables: medical innovation categories
We asked respondents to report how often they participated in any of the following 
activities during the year 2012. 
Responses could range from 0 (never) to more than 10 times.
Categories
DV 1: Commercialization
DV 2: New drug development
DV 3: Clinical guidelines
DV 4: Diagnostics and prevention
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 Factor analysis showed the existence of four categories / forms of medical innovation
 DVs: frequency in which scientists have participated in any of the activities listed in 
each category
Independent variables: brokerage roles
We followed an ego-centric network approach (e.g.: Baer, 2010; Smith et al., 2005) to capture
each scientist’ personal network structure and composition.
 Personal network size:
Respondents were asked to write down the names of those persons (up to ten)
from outside their research group that were of critical importance for the
advancement of their research activities.
 Personal network composition:
Respondents were asked to classify each of the contacts previously mentioned into any
of the following professional groups: 1=basic scientists, 2=clinical scientists, 3=medical
practitioners / patient representatives, 4=public administration, industry / other.
 Personal network structure: 
Respondents were presented an alter-alter matrix and were asked to report whether the 
set of contacts previously mentioned know each other.
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Independent variables: brokerage roles
 Personal network structure and content allowed us to compute the brokerage roles.
 We followed Gould and Fernandez (1989) procedure to count separately the number
of times each scientist is playing any of the four brokerage roles, based on the
afﬁliations of the three nodes involved in the triadic relationship.
 The same scientist can simultaneously play different brokerage roles. Example:
Basic scientist
Clinical scientist
Firm employee
Focal scientist is a clinical scientist with 6 direct contacts
He plays 12 brokerage roles:
Coordinator: n=1 (4-6)
Consultant: n=2 (5-3; 1-2)
Gatekeeper n=7 (4-5; 4-3; 4-1; 6-1; 6-2; 6-3; 6-5) 
Liaison: n=2 (5-1; 2-3)
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Frequency of brokerage roles
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 Most of the scientists do not play any brokerage role at all.
 Coordinator is the most frequent role. 
 Being a liaison is particularly rare
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Control variables and econometric model
• Individual level:
• Age
• Gender
• Academic position 
• External network size
• Group and Institutional level:
• Research team’s size
• Institutional affiliation: University, Hospital, PROs and Others
• Type of CIBER
• Research teams’ past scientific performance
• Research teams’ past technological performance
• Econometric model
• Our DVs are a count of scores, suggesting the use of a count model.
• DV is skewed. We used a negative binomial regression 
• Robustness check with Poisson and OLS 
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Main variables Commercialization Drug development Clinical guidelines
Diagnostics & 
prevention
Liaison 0.049* -0.021 0.037 0.048*
(0.03) (0.04) (0.03) (0.03)
Gatekeeper 0.047** 0.047** 0.041 0.055***
(0.02) (0.02) (0.03) (0.02)
Consultant 0.009 0.004 -0.021 -0.024
(0.02) (0.03) (0.03) (0.03)
Coordinator -0.017 -0.069*** -0.013 -0.061***
(0.02) (0.02) (0.03) (0.02)
Observations 1094 1095 1095 1095
Pseudo – R2 0.113 0.0864 0.0738 0.0496
* p < 0.1,  ** p < 0.05,  *** p < 0.01
Control variables: age, academic position, group size, institution type, CIBER, affiliation type, ego-network
size, gender, group scientific performance, group technological performance
Preliminary results: brokerage roles and medical innovation
H1
H2
Gatekeeper is positively 
related to 3 of 4 
innovation categories
Coordinator is negatively 
related to 2 of 4 
innovation categories
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Hospital Non – hospital
Main variables Commercializ.
Drug
development
Clinical
guidelines
Diagnostics & 
prevention Commercializ.
Drug
development
Clinical 
guidelines
Diagnostics & 
prevention
Liaison 0.063** 0.007 0.049 0.048 -0.004 -0.074 0.047 0.055
(0.03) (0.06) (0.03) (0.04) (0.07) (0.07) (0.07) (0.04)
Gatekeeper -0.028 0.059* -0.002 0.075** 0.068** 0.057 0.081** 0.053**
(0.03) (0.03) (0.03) (0.03) (0.03) (0.04) (0.04) (0.03)
Consultant 0.036 -0.052 -0.006 0.051 0.008 0.029 -0.044 -0.076**
(0.04) (0.04) (0.04) (0.06) (0.03) (0.06) (0.04) (0.03)
Coordinator -0.011 -0.026 0.017 -0.084** -0.019 -0.119*** -0.007 -0.044*
(0.04) (0.03) (0.02) (0.04) (0.02) (0.04) (0.04) (0.02)
Observations 396 397 397 397 698 698 698 698
Pseudo R2 0.144 0.0683 0.0837 0.102 0.131 0.0801 0.0795 0.0630
• p < 0.1,  ** p < 0.05,  *** p < 0.01
Preliminary results: distinctive effects in hospital / non-hospital settings
Split sample analysis. Scientists working at hospitals (n=397) vs scientists not working at 
hospitals (n=698)
Econometric model: negative binomial regression
H3
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Wald tests show significant differences on the predictive power of gatekeepers in both contexts.
Being a gatekeeper is particularly important in non-hospital settings as a facilitator of the participation in medical innovation
Contributions and preliminary conclusions
 Previous research on the relevance of brokerage to facilitate medical innovation has
been purely prescriptive or qualitative (e.g.: Currie & White, 2012, Waring et al., 2013).
 We provide empirical evidence that scientists occupying intermediate positions
between disconnected others will be more likely to engage in medical innovation.
 We adopted the Gould and Fernandez (1989) classification of brokerage types to
count the frequency that scientists hold liaison, gatekeeper, consultant and coordinator
positions.
 We emphasized the trade-off of benefits and costs of holding brokerage positions.
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Contributions and preliminary conclusions (ii)
 We found that the positive effects of brokerage is not that evident if the distinction
between brokerage roles is considered: gatekeeper provides the greater advantage.
 We found that the benefits of gatekeeper positions operate differently in hospital and non-
hospital settings, showing evidence of its critical importance for non-hospital scientists.
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Mean SD Min Max
Commercialization 0.267 1.133 0 28
Drug development 0.562 1.759 0 22
Clinical guidelines 0.514 1.392 0 14
Diagnostics and prevention 0.328 1.284 0 30
Liaison 0.483 1.871 0 27
Gatekeeper 2.265 4.500 0 25
Consultant 0.940 2.971 0 32
Coordinator 2.259 5.050 0 45
Large ego-network size 0.310 0.463 0 1
Age 41.894 10.651 23 78
Academic position 3.029 1.316 1 6
Group size 18.248 10.457 2 79
Institution type 2.050 0.874 1 4
CIBER 4.581 2.573 1 9
Affiliation type 1.850 0.511 1 3
Ego-network size < 2 0.265 0.442 0 1
Gender 1.531 0.499 1 2
Group scientific performance 53.943 46.351 3 295
Group technological performance 1.002 2.248 0 21
Descriptive statistics
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Dependent variables: medical innovation categories
Mean SD Min Max
DV 1: Commercialization 0.267 1.133 0 28
DV 2: Drug development 0.562 1.759 0 22
DV 3: Clinical guidelines 0.514 1.392 0 14
DV 4: Diagnostics and 
prevention 0.328 1.284 0 30
 Factor analysis revealed the existence of four distinct categories of medical innovation 
activities.
 Dependent variables: count of the frequency each scientist has been engaged in any
the activities of each category.
 Because they are count of scores, variables take on non-negative integer values
 We selected a negative binomial model to adress the overdispersion and the
prevalence of 0 counts in the DVs.
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Background: medical innovation and network brokerage
The biomedical field is an adequate context for the study of knowledge brokering for a number
of reasons:
 Many institutionalized occupational boundaries (e.g.: basic scientists, clinical scientists,
practitioners, patients) with different characteristics and interests (Currie et al., 2012).
 Need to reduce distance between these actors as a way to translate knowledge “from the
bench to the bedside” (Marincola, 2003)
 Thus, brokers are critical to translate, coordinate and align knowledge between disparate
communities, as well as to accelerate the diffusion of basic research evidence into clinical
practice (Waring et al., 2013).
Knowledge brokerage in the biomedical context
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Preliminary results: distinctive effects in hospital / non-hospital 
settings
We performed four Wald tests to take account of the covariance in the parameters across
the two models (hospitals vs non-hospitals). We compared the coefficients of Liaison,
Gatekeeper, Consultant and Coordinator in both models and for our four dependent
variables.
We found that:
 Occupying gatekeeper positions is particularly important among non-hospital
settings as an antecedent to their participation in medical innovation activities.
 Occupying liaison positions is particularly important for hospital scientists to
facilitate their engagement in commercialization activities.
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